Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stake Raised by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC boosted its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 63.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 311,846 shares of the company's stock after purchasing an additional 120,572 shares during the period. Exchange Traded Concepts LLC owned approximately 0.54% of Ginkgo Bioworks worth $1,778,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks in the 4th quarter valued at about $29,000. Price T Rowe Associates Inc. MD lifted its stake in Ginkgo Bioworks by 4.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock valued at $814,000 after purchasing an additional 3,152 shares during the last quarter. Green Alpha Advisors LLC lifted its stake in Ginkgo Bioworks by 31.7% during the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after purchasing an additional 4,449 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Ginkgo Bioworks during the fourth quarter valued at approximately $46,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Ginkgo Bioworks by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock valued at $412,000 after acquiring an additional 5,746 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

Shares of NYSE:DNA traded down $0.05 on Friday, reaching $8.53. 987,316 shares of the company traded hands, compared to its average volume of 1,460,314. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $17.46. The stock has a market capitalization of $499.44 million, a PE ratio of -0.93 and a beta of 1.25. The company's 50 day moving average is $7.78 and its 200-day moving average is $9.06.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. The firm had revenue of $48.32 million for the quarter, compared to analysts' expectations of $38.70 million. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.